Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Journal Volume
21
Journal Issue
6
Pages
1513
Date Issued
2023-06
Author(s)
Choi, Hannah S J
Hirode, Grishma
Chen, Chien-Hung
Seto, Wai-Kay
Van Hees, Stijn
Papatheodoridi, Margarita
Lens, Sabela
Wong, Grace L H
Brakenhoff, Sylvia M
Chien, Rong-Nan
Feld, Jordan J
Sonneveld, Milan J
Chan, Henry L Y
Forns, Xavier
Papatheodoridis, George V
Vanwolleghem, Thomas
Yuen, Man-Fung
Hsu, Yao-Chun
Cornberg, Markus
Hansen, Bettina E
Jeng, Wen-Juei
Janssen, Harry L A
Abstract
Whether entecavir (ETV) and tenofovir disoproxil fumarate (TDF) differentially affect relapse and outcomes following treatment discontinuation across different patient subpopulations remains unclear. We aimed to compare rates of off-therapy hepatitis B surface antigen (HBsAg) loss, virological and clinical relapse, and retreatment between chronic hepatitis B (CHB) patients who discontinued TDF or ETV therapy.
Subjects
Chronic Hepatitis B; Entecavir; Nucleos(T)Ide Analogue Withdrawal; Off-Therapy Outcomes; Tenofovir
SDGs
Type
journal article